Table 5.
Laboratory variables and weight parameters at baseline and after 8 weeks of maximally tolerated dose of carvedilol among 25 participants with intradialytic hypertension
| Baseline (n=25) | Study End (n=25) | Mean Change from Baseline to Study End | P Value | |
|---|---|---|---|---|
| Albumin (g/dl) | 3.8 (±0.55) | 3.8 (±0.35) | −0.01 (±0.30) | 0.8 |
| High-sensitivity C-reactive protein (mg/L) | 5.2 (1.5, 11.6) | 3.3 (1.5, 8.6) | −0.1 (−7.5, 0.7) | 0.6 |
| Hemoglobin (g/dl) | 12.3 (±1.1) | 12.2 (±1.0) | −0.16 (±1.5) | 0.6 |
| Serum sodium (mEq/L) | 135.8 (±3.7) | 136.1 (±3.5) | −0.2 (±2.6) | 0.7 |
| Total cholesterol (mg/dl) | 133.8 (±23.1) | 131.1 (±25.8) | −2.8 (±16.2) | 0.4 |
| LDL cholesterol (mg/dl) | 65.6 (±23.4) | 62.4 (±24.0) | −3.2 (±17.2) | 0.4 |
| HDL cholesterol (mg/dl) | 43.5 (±14.0) | 44.4 (±13.1) | 0.9 (±9.1) | 0.6 |
| Target dry weight, 2-wk average (kg) | 81.7 (±20.0) | 81.6 (±20.8) | −0.2 (±3.1) | 0.8 |
| Intradialytic weight loss, 2-wk average (kg) | 2.8 (±1.0) | 3.0 (±1.2) | −0.2 (±1.0) | 0.3 |
Values are reported as mean ± SD or medians and 25th to 75th interquartile ranges. P value determined from paired t tests or nonparametric signed rank tests.